Whether exogenous estrogen via hormone replacement therapy can upregulate central NOS, as endogenous estradiol does, and thereby increase the level of NO reducing sympathetic activation in postmenopausal women is usually unclear – Structure-Based Design of mTORC1 Inhibitors in Cancer Therapy